UC and Partners Awarded $23 Million to Transform Discoveries Into Real-World Health Solutions
CINCINNATIThe University of Cincinnati (UC) and its affiliated health care partners will receive nearly $23 million from the National Institutes of Health (NIH) to bring innovations from the laboratory bench to the bedside and to applications within the community.
The five-year funding, awarded through the NIHs institutional Clinical and Translational Science Awards (CTSA) program, will be used to support programming within UCs Center for Clinical and Translational Science and Training (CCTST). Established in 2005 as a collaborative effort among UC, Cincinnati Childrens Hospital Medical Center, University Hospital and the Cincinnati Department of Veterans Affairs Medical Center, the CCTST is a research resource and "academic home for clinical and translational scientists and programs.
UC is the first CTSA to be funded in 2009.
"Bench to bedside (translational research) is a common phrase in medicine, and turning laboratory findings into diagnostic tools or therapies for patients is the goal of academic medical centers, said David Stern, MD, College of Medicine dean and UC vice president for health affairs. "The CTSA program is a clear recognition by the NIH of the need to speed up the translation of the important work happening at the basic scientific level, and UCs award is indicative of the quality of scientific discovery happening on our campus and in the labs of our close partners.
CTSA fundingexpected to be given to only 60 institutions nationwide by 2012will eventually replace the NIHs General Clinical Research Center (GCRC) program and various other training programs.
UCs NIH-supported GCRC, housed at Cincinnati Childrens Hospital Medical Center, with a satellite operation at the Cincinnati Department of Veterans Affairs Medical Center, is led by James Heubi, MD, of Cincinnati Childrens and UCs department of pediatrics, and associate dean for clinical and translational research, and is credited with many research successes. UC faculty and Cincinnati Childrens and VA researchers working in the GCRC have been at the forefront of Reyes Syndrome and Gaucher disease, and have used novel medications to treat rare diseases such as lymphangioleiomyomatosis (LAM) and Fanconi anemia.
"Successes already realized at our NIH-supported clinical research center are strong indicators of what Cincinnati researchers and clinicians will be able to do with continued support and an emphasis on translational research, said Heubi, who leads UCs CTSA effort and the CCTST with Joel Tsevat, MD, professor of medicine and associate dean for clinical and translational research.
Heubi and Tsevat expect to continue whats been started with the CCTST and initiate additional partnerships that can help bring discoveries to application or engage the broader community in clinical and translational research efforts.
"The formation of the CCTST on UCs campus more than three years ago has put us in a unique position to hit the ground running with this CTSA award, says Tsevat. "Beyond serving our Academic Health Center, though, we plan to involve the community in clinical and translational research. Not only will we work to increase enrollment for our clinical studies, but we will also turn to the community for research topics. We envision a bi-directional relationship with the community.
UCs CCTST already offers research support, including study design and biostatistical expertise, individual and institutional training grant preparation assistance, clinical and translational research training, and funding opportunities for junior faculty so that they can develop their research programs and become viable candidates for larger awards from the NIH or other sources.
The CCTST has also helped departments obtain NIH training grants to support fellowship positions. Six of the 22 funded "T32 training grants on campus were obtained with CCTST assistance.
In addition to funding assistance, the CCTSTlocated on the 10th floor of Cincinnati Childrens new "S buildingis working to track clinical and translational activity and create an environment for researchers that facilitates interdisciplinary collaboration. The centers Research Central service provides investigators with consultations on their study design and execution of research projects.
The center also serves the universitys educational missionhelping to form the recently approved master of science in clinical and translational research program through UCs environmental health department.
The governance committee leading UCs CTSA effort includes Stern, Heubi and Tsevat, as well as James Anderson, president and CEO of Cincinnati Childrens; Sandra Degen, PhD, UC vice president for research; Lee Ann Liska, executive director of University Hospital; Linda Smith, director of the Cincinnati VA Medical Center; Arnold Strauss, MD, chair of UCs department of pediatrics and director of the Cincinnati Childrens Research Foundation; and UC President Nancy Zimpher.
For more information about the CTSA Consortium, visit www.ctsaweb.org. To read more about clinical and translational research at UC, visit www.cctst.uc.edu. A news release from the National Center for Research Resources can be found at http://www.nih.gov/news/health/apr2009/ncrr-07.htm.
ABOUT CTSA
The University of Cincinnati is one of 39 medical research institutions working together as a national
consortium to improve the way biomedical research is conducted across the country. The consortium, funded through the Clinical and Translational Science Awards (CTSA), shares a common vision to reduce the time it takes for laboratory discoveries to become treatments for patients, and to engage communities in clinical research efforts. It is also fulfilling the critical need to train clinical and translational researchers. The CTSA initiative is led by the National Center for Research Resources at the National Institutes of Health. For more information about the CTSA program, visit www.ncrr.nih.gov/crctsa.
James Heubi, MD (left), and Joel Tsevat, MD, associate deans for clinical and translational research at the UC College of Medicine.
Study researchers (left to right) Frank McCormack, MD, John Bissler, MD, and David Franz, MD.
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.